Related Experiment Video
Updated: May 8, 2026

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
Published on: December 7, 2014
Computational analysis of the binding specificity of Gleevec to Abl, c-Kit, Lck, and c-Src tyrosine kinases
1Department of Biochemistry and Molecular Biology, Gordon Center for Integrative Science, The University of Chicago , 929 57th Street, Chicago, Illinois 60637, United States.
Abstract:
Gleevec, a well-known cancer therapeutic agent, is an effective inhibitor of several tyrosine kinases, including Abl and c-Kit, but displays less potency to inhibit closely homologous tyrosine kinases, such as Lck and c-Src. Because many structural features of the binding site are highly conserved in these homologous kinases, the molecular determinants responsible for the binding specificity of Gleevec remain poorly understood. To address this issue, free energy perturbation molecular dynamics (FEP/MD) simulations with explicit solvent was used to compute the binding affinity of Gleevec to Abl, c-Kit, Lck, and c-Src. The results of the FEP/MD calculations are in good agreement with experiments, enabling a detailed and quantitative dissection of the absolute binding free energy in terms of various thermodynamic contributions affecting the binding specificity of Gleevec to the kinases. Dominant binding free energy contributions arises from the van der Waals dispersive interaction, compensating about two-thirds of the unfavorable free energy penalty associated with the loss of translational, rotational, and conformational freedom of the ligand upon binding. In contrast, the contributions from electrostatic and repulsive interactions nearly cancel out due to solvent effects. Furthermore, the calculations show the importance of the conformation of the kinase activation loop. Among the kinases examined, Abl provides the most favorable binding environment for Gleevec via optimal protein-ligand interactions and a small free energy cost for loss of the translational, rotational, and conformational freedom upon ligand binding. The FEP/MD calculations additionally reveal that Lck and c-Src provide similar nonbinding interactions with the bound-Gleevec, but the former pays less entropic penalty for the ligand losing its translational, rotational, and conformational motions to bind, examining the empirically observed differential binding affinities of Gleevec between the two Src-family kinases.
Insights
Gleevec effectively inhibits Abl and c-Kit kinases but not Lck or c-Src due to subtle structural differences. Free energy simulations reveal van der Waals interactions and kinase activation loop conformation dictate Gleevec
Area of Science:
- Biochemistry
- Computational Biology
- Pharmacology
Background:
- Gleevec is a cancer drug inhibiting tyrosine kinases like Abl and c-Kit.
- Its lower potency against homologous kinases (Lck, c-Src) is poorly understood.
- Conserved binding sites complicate Gleevec's specificity determinants.
Purpose of the Study:
- To computationally determine Gleevec's binding affinity to Abl, c-Kit, Lck, and c-Src.
- To dissect the thermodynamic contributions to Gleevec's kinase binding specificity.
- To elucidate the molecular basis for Gleevec's differential inhibition of kinases.
Main Methods:
- Free energy perturbation molecular dynamics (FEP/MD) simulations with explicit solvent.
- Calculation of absolute binding free energies for Gleevec with four kinases.
- Analysis of thermodynamic contributions (van der Waals, electrostatic, entropic penalties).
Main Results:
- FEP/MD results align well with experimental data.
- Van der Waals interactions are the dominant favorable contribution to binding.
- Kinase activation loop conformation significantly impacts Gleevec binding.
- Abl offers the most favorable binding environment for Gleevec.
- Lck and c-Src show similar non-binding interactions but differ in entropic penalties.
Conclusions:
- FEP/MD simulations successfully explain Gleevec's differential kinase binding.
- Binding specificity is governed by a balance of van der Waals forces and entropic costs.
- Protein-ligand interactions and conformational flexibility are key determinants of Gleevec's efficacy.

